tradingkey.logo

Insulet Corp

PODD
289.620USD
-3.260-1.11%
Cierre 12/19, 16:00ETCotizaciones retrasadas 15 min
20.37BCap. mercado
82.66P/E TTM

Más Datos de Insulet Corp Compañía

Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.

Información de Insulet Corp

Símbolo de cotizaciónPODD
Nombre de la empresaInsulet Corp
Fecha de salida a bolsaMay 15, 2007
Director ejecutivoMcevoy (Ashley)
Número de empleados3900
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 15
Dirección100 Nagog Park
CiudadACTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal01720-3440
Teléfono19786007000
Sitio Webhttps://www.omnipod.com
Símbolo de cotizaciónPODD
Fecha de salida a bolsaMay 15, 2007
Director ejecutivoMcevoy (Ashley)

Ejecutivos de Insulet Corp

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Director
Independent Director
27.70K
+2.89%
Mr. Michael R. Minogue
Mr. Michael R. Minogue
Independent Director
Independent Director
14.85K
-8.50%
Mr. Eric Benjamin
Mr. Eric Benjamin
Chief Operating Officer
Chief Operating Officer
10.47K
-28.94%
Ms. Ashley Mcevoy
Ms. Ashley Mcevoy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
9.54K
+238500.00%
Ms. Elizabeth H. (Bess) Weatherman
Ms. Elizabeth H. (Bess) Weatherman
Independent Director
Independent Director
5.24K
+17.43%
Ms. Lauren Budden
Ms. Lauren Budden
Chief Accounting Officer, Group Vice President, Corporate Controller
Chief Accounting Officer, Group Vice President, Corporate Controller
5.22K
+17.01%
Mr. Timothy C. (Tim) Stonesifer
Mr. Timothy C. (Tim) Stonesifer
Independent Director
Independent Director
3.85K
+33.25%
Ms. Laetitia Cousin
Ms. Laetitia Cousin
Senior Vice President - Regulatory Affairs, Quality Assurance and Compliance
Senior Vice President - Regulatory Affairs, Quality Assurance and Compliance
3.58K
--
Mr. Prem Singh
Mr. Prem Singh
Senior Vice President - Global Operations
Senior Vice President - Global Operations
3.56K
-16.16%
Dr. Luciana Borio, M.D.
Dr. Luciana Borio, M.D.
Independent Director
Independent Director
3.09K
-13.48%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Director
Independent Director
27.70K
+2.89%
Mr. Michael R. Minogue
Mr. Michael R. Minogue
Independent Director
Independent Director
14.85K
-8.50%
Mr. Eric Benjamin
Mr. Eric Benjamin
Chief Operating Officer
Chief Operating Officer
10.47K
-28.94%
Ms. Ashley Mcevoy
Ms. Ashley Mcevoy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
9.54K
+238500.00%
Ms. Elizabeth H. (Bess) Weatherman
Ms. Elizabeth H. (Bess) Weatherman
Independent Director
Independent Director
5.24K
+17.43%
Ms. Lauren Budden
Ms. Lauren Budden
Chief Accounting Officer, Group Vice President, Corporate Controller
Chief Accounting Officer, Group Vice President, Corporate Controller
5.22K
+17.01%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
Por negocioUSD
Nombre
Ganancia
Proporción
U.S.Omnipod
453.20M
69.82%
International Omnipod
185.80M
28.62%
Drug Delivery
10.20M
1.57%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
463.30M
71.38%
All Other
185.80M
28.62%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
U.S.Omnipod
453.20M
69.82%
International Omnipod
185.80M
28.62%
Drug Delivery
10.20M
1.57%

Estadísticas de accionistas

Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
12.46%
Fidelity Management & Research Company LLC
9.83%
Capital Research Global Investors
6.47%
BlackRock Institutional Trust Company, N.A.
6.29%
State Street Investment Management (US)
4.39%
Otro
60.56%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
12.46%
Fidelity Management & Research Company LLC
9.83%
Capital Research Global Investors
6.47%
BlackRock Institutional Trust Company, N.A.
6.29%
State Street Investment Management (US)
4.39%
Otro
60.56%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
64.92%
Investment Advisor/Hedge Fund
23.48%
Hedge Fund
4.88%
Pension Fund
2.61%
Research Firm
2.52%
Sovereign Wealth Fund
1.57%
Bank and Trust
1.22%
Individual Investor
0.30%
Family Office
0.05%

Participación institucional

Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
1546
72.07M
102.39%
-3.66M
2025Q2
1541
72.80M
103.47%
-3.81M
2025Q1
1569
72.82M
103.50%
-3.52M
2024Q4
1508
72.57M
103.34%
-4.94M
2024Q3
1436
73.14M
104.31%
-3.15M
2024Q2
1408
72.17M
103.04%
-3.02M
2024Q1
1350
71.60M
102.26%
-3.12M
2023Q4
1320
72.91M
104.42%
-1.52M
2023Q3
1254
72.05M
103.19%
-4.06M
2023Q2
1223
73.42M
105.35%
-3.44M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
8.68M
12.33%
+38.89K
+0.45%
Jun 30, 2025
Fidelity Management & Research Company LLC
6.86M
9.74%
-271.19K
-3.80%
Jun 30, 2025
Capital Research Global Investors
4.74M
6.73%
-1.34M
-22.06%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.35M
6.18%
-13.40K
-0.31%
Jun 30, 2025
State Street Investment Management (US)
3.06M
4.34%
+32.74K
+1.08%
Jun 30, 2025
Baillie Gifford & Co.
2.14M
3.03%
-115.69K
-5.14%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.93M
2.74%
+58.31K
+3.12%
Jun 30, 2025
ClearBridge Investments, LLC
1.54M
2.18%
+56.63K
+3.83%
Jun 30, 2025
American Century Investment Management, Inc.
1.31M
1.86%
+157.07K
+13.63%
Jun 30, 2025
Fidelity International
1.13M
1.61%
-155.38K
-12.09%
Jun 30, 2025
Ver más

ETFs relacionados

Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Langar Global HealthTech ETF
7.26%
Innovator IBD Breakout Opportunities ETF
4.88%
Global X HealthTech ETF
4.76%
Goldman Sachs Future Health Care Equity ETF
4.2%
First Trust Nasdaq Lux Digi Health Solutions ETF
3.7%
iShares Health Innovation Active ETF
3%
Congress SMid Growth ETF
2.82%
iShares U.S. Medical Devices ETF
2.62%
FT Raymond James Multicap Growth Equity ETF
2.3%
Acruence Active Hedge US Equity ETF
2.27%
Ver más
Langar Global HealthTech ETF
Proporción7.26%
Innovator IBD Breakout Opportunities ETF
Proporción4.88%
Global X HealthTech ETF
Proporción4.76%
Goldman Sachs Future Health Care Equity ETF
Proporción4.2%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporción3.7%
iShares Health Innovation Active ETF
Proporción3%
Congress SMid Growth ETF
Proporción2.82%
iShares U.S. Medical Devices ETF
Proporción2.62%
FT Raymond James Multicap Growth Equity ETF
Proporción2.3%
Acruence Active Hedge US Equity ETF
Proporción2.27%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Insulet Corp?

Los cinco principales accionistas de Insulet Corp son:
The Vanguard Group, Inc. posee 8.68M acciones, lo que representa el 12.33% del total de acciones.
Fidelity Management & Research Company LLC posee 6.86M acciones, lo que representa el 9.74% del total de acciones.
Capital Research Global Investors posee 4.74M acciones, lo que representa el 6.73% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 4.35M acciones, lo que representa el 6.18% del total de acciones.
State Street Investment Management (US) posee 3.06M acciones, lo que representa el 4.34% del total de acciones.

¿Cuáles son los tres principales tipos de accionista de Insulet Corp?

Los tres principales tipos de accionista de Insulet Corp son:
The Vanguard Group, Inc.
Fidelity Management & Research Company LLC
Capital Research Global Investors

¿Cuántas instituciones poseen acciones de Insulet Corp (PODD)?

A fecha de 2025Q3, 1546 instituciones poseen acciones de Insulet Corp, con un valor de mercado combinado de aproximadamente 72.07M, lo que representa el 102.39% del total de acciones. En comparación con el 2025Q2, el accionariado institucional ha aumentado en -1.08%.

¿Cuál es la mayor fuente de ganancias de Insulet Corp?

El FY2025Q2, el segmento empresarial U.S.Omnipod generó la ganancia más alta para Insulet Corp, ascendiendo a 453.20M y representando el 69.82% de la ganancia total.
KeyAI